Ageism in Indonesia’s national covid-19 vaccination programme
- 2 February 2021
- Vol. 372, n299
- https://doi.org/10.1136/bmj.n299
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Equitable global access to coronavirus disease 2019 vaccines Vaccines will be as challenging to deliver as they were to developBMJ, 2020
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2020
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trialTrials, 2020
- A classification of the aims of vaccination and its relevance to transgenerational justiceJournal of Global Health, 2020
- Institutional ageism in global health policyBMJ, 2016